Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio para comparar los resultados a largo plazo después de dos anestésicos diferentes (TREX)

9 de noviembre de 2026 actualizado por: Murdoch Childrens Research Institute

Resultado del desarrollo neurológico después de la anestesia con dosis estándar de sevoflurano versus dosis bajas de sevoflurano/dexmedetomidina/remifentanilo en niños pequeños: el ensayo TREX

There is considerable evidence that most general anaesthetics modulate brain development in animal studies. The impact is greater with longer durations of exposure and in younger animals. There is great controversy over whether or not these animal data are relevant to human clinical scenarios.

The changes seen in preclinical studies are greatest with GABA agonists and NMDA antagonists such as volatile anaesthetics (eg sevoflurane), propofol, midazolam, ketamine, and nitrous oxide. There is less evidence for an effect with opioid (such as remifentanil) or with alpha 2 agonists (such as dexmedetomidine).

Some, but not all, human cohort studies show an association between exposure to anaesthesia in infancy or early childhood and later changes in cognitive tests, school performance or risk of developing neurodevelopmental disorders. The evidence is weak due to possible confounding.

A recent well designed cohort study (the PANDA study) comparing young children that had hernia repair to their siblings found no evidence for a difference in a range of detailed neuropsychological tests. In that study most children were exposed to up to two hours of anaesthesia. The only trial (the GAS trial) has compared children having hernia repair under regional or general anesthesia and has found no evidence for a difference in neurodevelopment when tested at two years of age. The GAS and PANDA studies confirm the animal data that short exposure is unlikely to cause any neurodevelopmental impact.

The impact of longer exposures is still unknown. In humans the strongest evidence for an association between surgery and poor neurodevelopmental outcome is in infants having major surgery. However, this is also the group where confounding is most likely.

The aim of our study is to see if a new combination of anaesthetic drugs results in a better long-term developmental outcome than the current standard of care for children having anaesthesia expected to last 2 hours or longer.

Children will be randomised to receive either a low dose sevoflurane/remifentanil/dexmedetomidine or standard dose sevoflurane anaesthetic.

They will receive a neurodevelopmental assessment at 3 years of age to assess global cognitive function.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Actual)

450

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • New South Wales
      • Randwick, New South Wales, Australia, 2031
        • Sydney Children's Hospital
      • Westmead, New South Wales, Australia, 2145
        • Children's Hospital at Westmead
    • Queensland
      • Brisbane, Queensland, Australia, 4101
        • Queensland Children's Hospital
    • South Australia
      • Adelaide, South Australia, Australia, 5006
        • Women's and Children's Hospital
      • Bedford Park, South Australia, Australia, 5042
        • Flinders Medical Centre
    • Victoria
      • Parkville, Victoria, Australia, 3052
        • Royal Children's Hospital
    • Western Australia
      • Perth, Western Australia, Australia, 6008
        • Perth Children's Hospital
      • Madrid, España
        • La Paz University Hospital
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02115
        • Boston Children's Hospital
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44195
        • Cleveland Clinic
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • The Children's Hospital of Philadelphia
    • Texas
      • Dallas, Texas, Estados Unidos, 75390
        • The University of Texas Southwestern Medical Center
      • Houston, Texas, Estados Unidos, 77030
        • Texas Children's Hospital
      • Alessandria, Italia
        • Presidio Ospedale Infantile C.Arrigo Azienda Ospedaliera
      • Bologna, Italia
        • Azienda ospedaliero-universitaria di Bologna
      • Florence, Italia
        • Azienda Ospedaliero-Universitaria Meyer
      • Genova, Italia
        • Istituto Giannina Gaslini
      • Milan, Italia
        • Vittore Buzzi Children's Hospital
      • Milan, Italia
        • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico - Clinica Mangiagalli
      • Pisa, Italia
        • Azienda Ospedaliero Universitaria Pisana
      • Roma, Italia
        • Ospedale Bambino Gesù

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

No mayor que 2 años (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Younger than 2 years (chronological age)
  • Scheduled for anaesthesia that is expected to last at least 2 hours (and/or total operating room time is scheduled to be at least 2.5 hours)
  • Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf.

Exclusion Criteria:

  • Known neurologic, chromosomal or congenital anomaly which is likely to be associated with poor neurobehavioural outcome
  • Existing diagnosis of behavioural or neurodevelopmental disability
  • Prematurity (defined as < 36 weeks gestational age at birth)
  • Birth weight less than 2 kg.
  • Congenital cardiac disease requiring surgery
  • Intracranial neurosurgery and intracranial craniofacial surgery (isolated cleft lip is not an exclusion)
  • Previous cumulative exposure to general anaesthesia exceeding 2 hours
  • Planned future cumulative exposure to anaesthesia exceeding 2 hours before the age of 3 years.
  • Any specific contra-indication to any aspect of the protocol
  • Previous adverse reaction to any anaesthetic
  • Circumstances likely to make long term follow-up impossible
  • Living in a household where the primary language spoken at home is not a language in which we can administer the Wechsler Preschool and Primary School Intelligence Scale
  • Planned postoperative sedation with any agent except opioids (e.g. benzodiazepines, dexmedetomidine, ketamine, barbiturates, propofol, clonidine, chloral hydrate, and other non-opioid sedatives). For example if such sedation is planned for post-operative ventilation

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Sevoflurane/dexmedetomidine/remifentanil

Dexmedetomidine: loading dose of 1mcg/kg over 10 minutes followed by an infusion of at 1 mcg/kg/hr.

Remifentanil: loading dose 1 mcg/kg over 2 minutes followed by an infusion starting at 0.1 mcg/kg/min or greater.

Sevoflurane: end tidal concentration of 0.6 -0.8% or less.

Experimental arm: end tidal concentration of 0.6 -0.8% or less. Active comparator arm: end tidal concentration of 2.5-3.0% or greater.

Otros nombres:
  • Sevorane

Experimental arm: loading dose: 1 mcg/kg, infusion starting at 0.1 mcg/kg/min or greater.

Otros nombres:
  • Ultiva

Experimental arm: loading dose:1mcg/kg, infusion: 1 mcg/kg/hr.

Otros nombres:
  • Precedente
  • Dexmedetomidina Ever Pharma
Comparador activo: Sevoflurane

End tidal concentration of 2.5-3.0% or greater.

Experimental arm: end tidal concentration of 0.6 -0.8% or less. Active comparator arm: end tidal concentration of 2.5-3.0% or greater.

Otros nombres:
  • Sevorane

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Full Scale IQ
Periodo de tiempo: 3 years of age

Global cognitive function as assessed by the full scale IQ score of the Wechsler Preschool and Primary School Intelligence Scale.

3 years of age

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
incidence of intra-operative hypotension
Periodo de tiempo: 150 minutes- duration of surgery (baseline)

Blood pressure measurements will be recorded during surgery

150 minutes- duration of surgery (baseline)
incidence of intra-operative bradycardia
Periodo de tiempo: 150 minutes- duration of surgery (baseline)

Heart rate will be recorded during surgery

150 minutes- duration of surgery (baseline)
Post-operative pain
Periodo de tiempo: 60 minutes- after surgery

Pain scores will be recorded after surgery

60 minutes- after surgery
Time to recovery
Periodo de tiempo: 60 minutes- after surgery

Time of removal of airway, eye-opening and discharge from PACU will be recorded.

60 minutes- after surgery
Language outcomes
Periodo de tiempo: 3 years of age

Clinical Evaluation of Language Fundamentals- Preschool, Version 2 (CELF-P2)

3 years of age
Attention/Executive Function/impulse control
Periodo de tiempo: 3 years of age

A Developmental NEuroPSYchological Assessment- Second Edition (NEPSY-2): Statue Subtest

3 years of age
Memory
Periodo de tiempo: 3 years of age

A Developmental NEuroPSYchological Assessment- Second Edition (NEPSY-2): Narrative memory

3 years of age
Adaptive behaviour
Periodo de tiempo: 3 years of age

Adaptive Behavior Assessment System - Third Edition (ABAS-III)

3 years of age
Clinical Behavior
Periodo de tiempo: 3 years of age

Child Behavior Checklist (CBCL)

3 years of age
Executive Function
Periodo de tiempo: 3 years of age

Behavior Rating of Executive Function- Preschool (BRIEF-P)

3 years of age
Social Skills
Periodo de tiempo: 3 years of age

Social Skills Improvement System (SSIS)

3 years of age

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

10 de agosto de 2017

Finalización primaria (Estimado)

1 de diciembre de 2026

Finalización del estudio (Estimado)

1 de diciembre de 2026

Fechas de registro del estudio

Enviado por primera vez

8 de marzo de 2017

Primero enviado que cumplió con los criterios de control de calidad

19 de marzo de 2017

Publicado por primera vez (Actual)

24 de marzo de 2017

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

9 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

The de-identified data set collected for this analysis of the TREX trial will be available six months after publication of the primary outcome.

The study protocol, analysis plan and consent forms will also be available. The data may be obtained from the Murdoch Children's Research Institute by emailing andrew.davidson@rch.org.au.

Marco de tiempo para compartir IPD

6 months after publication of primary outcome

Criterios de acceso compartido de IPD

Prior to releasing any data the following are required: a data access agreement must be signed between relevant parties, the TREX Trial Steering Committee must see and approve the analysis plan describing how the data will be analysed, there must be an agreement around appropriate acknowledgement and any additional costs involved must be covered. Data will only be shared with a recognised research institution which has approved the proposed analysis plan.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF
  • CÓDIGO_ANALÍTICO
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir